Browse the latest research summaries in the field of pain management for spinal cord injury patients and caregivers.
Showing 421-430 of 682 results
Molecular Pain, 2021 • January 1, 2021
In healthy adult rodents, descending serotonergic modulation inhibits nociceptive transmission via 5-HT1a, 5-HT1b, 5-HT2c, 5-HT3, and 5-HT4 receptors. In chronic pain, this balance shifts towards faci...
KEY FINDING: In healthy rodents, serotonin generally inhibits pain signals in the spinal cord via receptors like 5-HT1a, 5-HT1b, 5-HT2c, 5-HT3, and 5-HT4.
J Neural Eng, 2022 • January 1, 2022
This study investigates the potential of motor-targeted intraspinal microstimulation (ISMS) to simultaneously modulate spinal nociceptive transmission. The researchers characterized the neuromodulator...
KEY FINDING: Sub-motor threshold ISMS delivered to spinal motor pools immediately modulates concurrent nociceptive transmission
Cells, 2022 • September 30, 2022
This review examines the potential of activity-based interventions (ABI) to alleviate neuropathic pain (NP) following spinal cord injury (SCI) in preclinical rodent models. It focuses on molecular and...
KEY FINDING: Weight-bearing rhythmic activity-based paradigms seem effective for neuropathic pain relief after spinal cord injury, regardless of whether interventions are started early or delayed, or applied for short or long durations, but the benefits may not persist long after halting the interventions.
Spinal Cord Series and Cases, 2022 • September 30, 2022
This case report describes a rare instance of spinal cord compression caused by a spinal cord stimulator (SCS) electrode array in a 58-year-old woman with a history of back pain and multiple spine sur...
KEY FINDING: The case report highlights a very rare complication of SCS, spinal cord compression due to the electrode array.
Mediators of Inflammation, 2022 • September 30, 2022
The study investigates the effects of LPA on spinal cord neurons, particularly concerning cytotoxicity, apoptosis, DNA damage, and oxidative stress, using an in vitro model. It finds that LPA (18:1) n...
KEY FINDING: LPA (18:1) treatment decreases cell viability and increases LDH release in spinal cord neurons, indicating cytotoxicity.
Evidence-Based Complementary and Alternative Medicine, 2022 • October 7, 2022
This study investigates the analgesic effects of electroacupuncture (EA) on neuropathic pain in a chronic constriction injury (CCI) rat model. The research focuses on the role of GABAA receptors and m...
KEY FINDING: EA treatment relieves mechanical allodynia and thermal hyperalgesia in CCI rats, as demonstrated by increased MWT and TWL values compared to the CCI group.
Journal of Neuroinflammation, 2022 • November 8, 2022
The study investigated the connection between neuropathic pain (NP) and neuroinflammation (NIF) following spinal cord injury (SCI) in rats. The researchers explored whether NP coexists with changes in...
KEY FINDING: SCI resulted in impaired sensorimotor functions, altered reflexes, and hypersensitivity to painful stimuli.
Top Spinal Cord Inj Rehabil, 2022 • October 1, 2022
This phase I randomized controlled trial will investigate the effectiveness of cognitive multisensory rehabilitation (CMR) for neuropathic pain relief in adults with spinal cord injury (SCI). The stud...
KEY FINDING: The study aims to determine baseline differences in brain function between adults with SCI and uninjured controls using fMRI.
Spinal Cord Series and Cases, 2022 • November 29, 2022
This study reviewed the use of phenol neurolysis for spasticity management in 66 people with spinal cord injury (SCI). The study found that phenol neurolysis, guided by electrical stimulation and ultr...
KEY FINDING: The obturator nerve (33%) and pectoral nerves (23%) were the most frequent targets for phenol neurolysis in people with SCI.
Neurology® 2023 • March 14, 2023
This phase 3 study evaluated the efficacy and safety of mirogabalin for treating central neuropathic pain (CNeP) in Asian patients with spinal cord injury (SCI). The study found that mirogabalin signi...
KEY FINDING: Mirogabalin significantly improved pain compared to placebo, as measured by the weekly average daily pain score (ADPS) at week 14.